PAC-1 is under clinical development by Vanquish Oncology and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PAC-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PAC-1 overview

PAC-1 (also known as VO-100) is under development for the treatment of anaplastic astrocytoma, glioblastoma multiforme (gbm), neuroendocrine tumors, lymphoma, pancreatic neuroendocrine tumor and solid tumors. The drug candidate is formulated as a capsule and administered orally and it acts by targeting a cellular enzyme, procaspase-3.

It was under development for metastatic uveal melanoma.

Vanquish Oncology overview

Vanquish Oncology is a biotechnology company which develops targeted, small-molecule oncology therapeutics for unmet or underserved cancer markets. The company is headquartered in Champaign, Illinois, the US.

For a complete picture of PAC-1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.